Medline (MDLN) Q1 FY26 earnings call: guidance and Q&A

How much lead time will Medline give clients/manufacturers for price changes due to rising input costs, and how do tariff assumptions factor into reiterated EBITDA guidance?

Medline has not determined price increases for Middle East conflict impacts, evaluating the situation. Historically, tariff-related price increases had 45-60 days notice, but they absorbed costs first. The reiterated EBITDA guidance accounts for Middle East conflict, investments, and tariff favorability.

“We have not made a determination yet that we're going to raise prices as it relates to the Middle East comp it. We still continue to evaluate the impact to our business, how long this may last.”

asked by Michael Cherny · answered by Michael Drazin

Is the maintained EBITDA guidance, despite raised revenue guidance, due to faster implementation driving higher OpEx? Is there conservatism around input costs from the Middle East conflict?

Raised organic sales guidance reflects strong Q1 performance. Maintained EBITDA guidance balances Middle East conflict, investments, and tariff favorability. The situation is dynamic, and they will take a measured approach to input costs, not reacting too quickly.

“On the EBITDA side, we have held EBITDA at $3.5 billion to $3.6 billion in the face of both the Middle East conflict additional investment in our business, offset by some favorability from tariffs.”

asked by Charles Rhyee · answered by James Boyle

Provide more detail on Q1 prime vendor signings, given strong 2025, and expectations going forward.

Q1 saw a strong start to new prime vendor signings, in line with expectations. They are not giving quarterly numbers due to lumpiness but expect to achieve their annual goal of $1 billion in new prime vendor signings.

“We aren't giving quarterly kind of actual numbers on that because as you know, that can be lumpy. You can extrapolate. If we did $500 million this quarter, it doesn't mean we're going to do $500 million -- that's a made-up number.”

asked by Patrick Donnelly · answered by James Boyle

Understand the puts and takes on supply chain business profitability in Q1 and whether the 2025 PV ramp is on schedule.

Supply Chain Solutions had strong top-line growth (15% reported, 17% adjusted for days) but EBITDA was slightly behind due to customer mix and investments in sales, operations, and IT. The 2025 PV ramp is on schedule: 25% revenue realization in 2025, 65% in 2026, and the rest in 2027.

“From an EBITDA perspective, EBITDA came in a little bit behind our expectations, but really driven by the fact that we had both some mix as it relates to new customer signings and the margin on those new customer signings given the size of those implementation, but also given the investments in our business.”

asked by Elizabeth Anderson · answered by Michael Drazin

How much work is happening on longer-term mitigation efforts (changing countries, partners) for tariffs, and when will benefits flow through?

Diversification and multi-sourcing (90% of Medline brand products multi-sourced, up 10% in 5 years) are core to their strategy, allowing agility in sourcing. They are buying in advance and building inventory to manage challenges like oil price impacts on NBR and fuel. They will continue to leverage their playbook to mitigate internally before passing costs to customers.

“That's part of having over 90% of our products from Medline brand have multiple sourcing options and that's up 10% as we talked about from 5 years ago.”

asked by Sean Dodge · answered by James Boyle

Comment on utilization trends given broad lens, especially concerns about softening due to ACA expiries or macro uncertainty.

Q1 saw consistent utilization, but some softening is anticipated in H2 due to reimbursement cuts and lack of insurance access. However, this could lead to higher acuity cases, potentially balancing the overall cost impact.

“We can tell you in the first quarter, we didn't see much change in utilization. The -- really, the acceleration in growth for us is share gains, but the actual utilization seemed pretty consistent are on par with what we expected.”

asked by Matthew Taylor · answered by James Boyle

How many days of inventory for Medline brand vs. supply chain solutions? Break out inflationary pressures for both segments and quantify if current costs remain stable.

Overall, 80 days of inventory, with more for Medline brand. Tariff impact of $120M ($85M incremental) in Q1, with remaining higher-cost inventory sold in Q2. Favorability from 10% tariff rate expected in H2. Middle East impact on fuel costs (diesel >$5/gallon) in Q2, but biggest impact on petroleum-based products (nitrile exam gloves, resins, plastics) in P&L expected late Q2/early Q3. Tariff favorability offsets Middle East impact.

“On an inventory basis, we carry about 80 days inventory on hand overall. We carry more on the Medline brand side, less obviously, in the supply chain solution side.”

asked by Pito Chickering · answered by James Boyle

Updated expectations for Section 232 tariffs on PPE/medical consumables? Leverage target and M&A priority in current environment?

Expect 122 tariffs to run out end of July, administration may use 232 or 301. Medline will monitor and work with administration. Ended Q1 with 3.1x net leverage and $2.2B cash. Priority is organic investment, then M&A for strategic growth, then debt reduction.

“As it relates to leverage, we ended the quarter with 3.1x leverage. We carry about $2 billion -- $2.2 billion of cash on hand.”

asked by Navann Ty · answered by James Boyle